Literature DB >> 8813140

Excision of 2',2'-difluorodeoxycytidine (gemcitabine) monophosphate residues from DNA.

V Gandhi1, J Legha, F Chen, L W Hertel, W Plunkett.   

Abstract

The activity of gemcitabine (dFdC), an effective agent against solid tumors, depends on the incorporation of its triphosphate into DNA. In vitro investigations demonstrated that, depending on the sequence of template DNA, polymerases may pause after incorporation of gemcitabine nucleotide at either the 3'-terminal or 3'-penultimate position. Proofreading enzymes such as 3'-->5' exonucleases, which are associated with DNA polymerases, can excise mismatched deoxynucleotides from DNA. To model this reaction, we evaluated excision of the gemcitabine nucleotide from oligodeoxynucleotide (19-mer) containing 3'-penultimate dFdC monophosphate (dFdCMP) or dCMP by the 3'-->5' exonuclease of the Klenow fragment. The rate of excision of the 3'-terminal deoxynucleotide was similar, with both primers resulting in formation of primers with terminal dCMP or dFdCMP. The primer containing dCMP was further excised, and by 40 min, more than 75% of total radioactivity was in excision products smaller than 18-mer. In contrast, most of the primers (90%) with terminal dFdCMP were unexcised. When primers terminated with either dFdCMP or dCMP were used as substrates, normal primer was hydrolyzed almost completely by 20 min; however, only 40% of primers containing dFdCMP had excision of dFdCMP molecule. Kinetic studies demonstrated that the enzyme had similar affinity for primers containing penultimate or terminal dFdCMP, but the apparent Vmax for excision was 4-5-fold greater for removal of a 3'-terminal deoxynucleotide than for cleavage of a dFdCMP molecule. Reaction conditions that permitted polymerization of one deoxynucleotide to primers containing either 3'-penultimate dCMP or dFdCMP were used to evaluate excision during DNA synthesis. The excised primers could not be extended because the reaction lacked the requisite deoxynucleotide triphosphate. After 5 min, more than one-half of the dCMP primers were extended, whereas only 15% had been excised. In comparison, 30% of the analogue-containing primers lost the terminal deoxynucleotide, with a proportional lower incidence of extension (30%). Lesser excision of dFdCMP-containing substrate was observed in reactions containing deoxynucleotide triphosphates required to make full-length products. Consistent with this result, in the absence of 3'-->5' exonuclease activity, both primers were extended similarly by the polymerization unit of the Klenow fragment. Taken together, these data demonstrate that dFdCMP residues are difficult to excise from DNA, and DNA polymerase can extend primers with 3'-dFdCMP. This results in the internal incorporation of dFdCMP into DNA, as observed in whole cells.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8813140

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  17 in total

1.  Enhanced subunit interactions with gemcitabine-5'-diphosphate inhibit ribonucleotide reductases.

Authors:  Jun Wang; Gregory J S Lohman; JoAnne Stubbe
Journal:  Proc Natl Acad Sci U S A       Date:  2007-08-28       Impact factor: 11.205

Review 2.  Pharmacogenetics and pharmacoepigenetics of gemcitabine.

Authors:  M Candelaria; E de la Cruz-Hernández; E Pérez-Cárdenas; C Trejo-Becerril; O Gutiérrez-Hernández; A Dueñas-González
Journal:  Med Oncol       Date:  2009-11-10       Impact factor: 3.064

3.  Hyperthermia inhibits recombination repair of gemcitabine-stalled replication forks.

Authors:  Mustafa Raoof; Cihui Zhu; Brandon T Cisneros; Heping Liu; Stuart J Corr; Lon J Wilson; Steven A Curley
Journal:  J Natl Cancer Inst       Date:  2014-08-15       Impact factor: 13.506

Review 4.  DNA polymerase eta and chemotherapeutic agents.

Authors:  Kai-ming Chou
Journal:  Antioxid Redox Signal       Date:  2011-03-18       Impact factor: 8.401

Review 5.  Enzymology of purine and pyrimidine antimetabolites used in the treatment of cancer.

Authors:  William B Parker
Journal:  Chem Rev       Date:  2009-07       Impact factor: 60.622

6.  Intracellular pharmacokinetics of gemcitabine, its deaminated metabolite 2',2'-difluorodeoxyuridine and their nucleotides.

Authors:  Ellen J B Derissen; Alwin D R Huitema; Hilde Rosing; Jan H M Schellens; Jos H Beijnen
Journal:  Br J Clin Pharmacol       Date:  2018-04-16       Impact factor: 4.335

7.  An increase of cytochrome C oxidase mediated disruption of gemcitabine incorporation into DNA in a resistant KB clone.

Authors:  Xiyong Liu; Bingsen Zhou; Shu Mi; Lijun Xue; Jennifer Shih; Janice Lee; Jennifer Chau; Frank Un; Yun Yen
Journal:  Biochem Pharmacol       Date:  2007-03-20       Impact factor: 5.858

Review 8.  Chemotherapeutic agents for the treatment of hepatocellular carcinoma: efficacy and mode of action.

Authors:  Saad Shaaban; Amr Negm; Elsayed E Ibrahim; Ahmed A Elrazak
Journal:  Oncol Rev       Date:  2014-05-28

9.  One-electron oxidation of gemcitabine and analogs: mechanism of formation of C3' and C2' sugar radicals.

Authors:  Amitava Adhikary; Anil Kumar; Ramanjaneyulu Rayala; Ragda M Hindi; Ananya Adhikary; Stanislaw F Wnuk; Michael D Sevilla
Journal:  J Am Chem Soc       Date:  2014-10-23       Impact factor: 15.419

10.  Effects of gemcitabine on APE/ref-1 endonuclease activity in pancreatic cancer cells, and the therapeutic potential of antisense oligonucleotides.

Authors:  J P Lau; K L Weatherdon; V Skalski; D W Hedley
Journal:  Br J Cancer       Date:  2004-09-13       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.